bextra news bextra lawyers canada

Health Canada Wants Arthritis Drug Bextra Off market

bextra lawsuit
CBC News

April 7, 2005—Health Canada asked drug maker Pfizer on Thursday to immediately discontinue sales of its arthritis drug Bextra, the same day sales were suspended in the U.S. and Europe until concerns about its safety are cleared up.

Pfizer suspended sales of the drug in the United States and the European Union following a request from the U.S. Food and Drug Administration and European regulators.

In seeking Bextra's withdrawal, Pfizer says the FDA cited a risk of the drug causing a potentially fatal skin reaction.

Pfizer says it disagrees with the FDA and Health Canada on Bextra's safety.

Health Canada says it will request more safety information from Pfizer regarding Bextra.

The FDA also wants other drugs in the same class, known as COX-2 inhibitors, to carry the strongest possible safety warning about increased risk of heart attack and stroke. Pfizer's Celebrex is included in that class, as well as Merck & Co.'s high-profile drug Vioxx.

The regulator said it called for Bextra's withdrawal from store shelves because of the skin condition risk.

The FDA is also asking for strengthened warnings on Motrin, Advil and Aleve—known as over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs)—about the risks of cardiovascular problems and gastrointestinal bleeding. The warnings do not apply to Aspirin.

Celebrex, Vioxx and Bextra are selective NSAIDs, designed to prevent gastrointestinal bleeding.

The regulator has been studying the safety of COX-2 inhibitors since Merck & Co. pulled Vioxx from the market last September, citing research that showed links to an increased risk of heart attack and stroke.

The first COX-2 inhibitors were introduced to the market in 1999, promoted as safe, effective drugs that would target an enzyme responsible for pain and inflammation without causing stomach distress, as earlier generations of arthritis drugs had done.

Bextra News

Pfizer and U.S. Settle Bextra, Other Probes
Bloomberg News
January 27, 2009
Bextra Not To Be Sold in Canada: Ruling
Canadian Press
December 17, 2005
Another Painkiller, Bextra, Pulled at Health Canada's Request
The Globe and Mail
April 8, 2005

Contact Us

Name
Phone
Email

About Our Lawyers

Greg Monforton and Partners has grown to a highly respected products liability law firm with offices conveniently located throughout Windsor and Essex County, together with affiliate relationships with law firms throughout Ontario, Canada and the United States.

We are committed to protecting the rights of individuals injured by defective products. The firm never represents insurance companies or product manufacturers. We only help people.